Prostate Cancer News and Research RSS Feed - Prostate Cancer News and Research Twitter

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
Further Reading
Robotically-steered flexible needles may improve diagnostic and therapeutic procedures

Robotically-steered flexible needles may improve diagnostic and therapeutic procedures

Robotically steering flexible needles can reach their intended target in tissue with sub-millimetre level accuracy. This has been demonstrated by the doctoral research of Momen Abayazid, who is affiliated with the research institute MIRA of the University of Twente. An major advantage of steering flexible needles is that one can avoid obstacles or sensitive tissues and can re-orient the path of the needle in real time as you insert the needle. [More]
Researchers design online database to help researchers identify cancer gene mutations

Researchers design online database to help researchers identify cancer gene mutations

Many clinical trials use genome sequencing to learn which gene mutations are present in a patient's tumor cells. The question is important because targeting the right mutations with the right drugs can stop cancer in its tracks. But it can be difficult to determine whether there is evidence in the medical literature that particular mutations might drive cancer growth and could be targeted by therapy, and which mutations are of no consequence. [More]
New research finds five different types of prostate cancer

New research finds five different types of prostate cancer

New research has revealed that five different types of prostate cancer exist. How will this discovery change the outlook of prostate cancer screening? World renowned robotic prostate cancer surgeon, Dr. David Samadi, evaluates. [More]
Electronic triggers can help identify, reduce follow-up delays in evaluation for cancer diagnosis

Electronic triggers can help identify, reduce follow-up delays in evaluation for cancer diagnosis

Electronic triggers designed to search for key data, developed by researchers at Baylor College of Medicine and Michael E. DeBakey Veterans Affairs Medical Center, were able to identify and reduce follow-up delays for patients being evaluated for a diagnosis of colon or prostate cancer. [More]
Berg and University of Miami extend partnership to battle cardiac dysfunction, heart failure

Berg and University of Miami extend partnership to battle cardiac dysfunction, heart failure

Berg, a Boston-based biopharmaceutical company, and the University of Miami Leonard M. Miller School of Medicine are extending its collaboration to battle cardiac dysfunction and heart failure. According to the American Heart Association, cardiovascular disease is the leading global cause of death, accounting for 17.3 million deaths per year, a number that is expected to grow to more than 23.6 million by 2030. [More]
NW Bio's DCVax-L Phase III trial ongoing for treatment of patients with newly diagnosed GBM

NW Bio's DCVax-L Phase III trial ongoing for treatment of patients with newly diagnosed GBM

Northwest Biotherapeutics, a U.S. biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, confirmed today that its Phase III trial of DCVax-L for newly diagnosed glioblastoma multiforme (GBM) is ongoing and the patients enrolled in the trial are continuing to be treated per the protocol. [More]
MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

MTG Biotherapeutics, an immuno-oncology company developing novel therapeutics for the treatment of cancer, today announced that the US Food and Drug Administration has granted Orphan Drug Designation for MTG-201, an advanced biologic therapy targeting Dickkopf-3 gene defects in various cancers, for the treatment of malignant mesothelioma. [More]
PSMA PET imaging more precise than MR imaging for detection of high-grade prostate cancer lesions

PSMA PET imaging more precise than MR imaging for detection of high-grade prostate cancer lesions

A molecular imaging biomarker is able to detect fast-growing primary prostate cancer and distinguish it from benign prostate lesions, addressing an unmet clinical need. The new research, published in the July 2015 issue of The Journal of Nuclear Medicine, is significant for patients with suspected prostate cancer that has not been confirmed by standard biopsy. [More]
Johns Hopkins experts say hospital consolidation may reduce patient choice, increase medical expenses

Johns Hopkins experts say hospital consolidation may reduce patient choice, increase medical expenses

In a commentary published in the Aug. 13 issue of JAMA, Johns Hopkins experts say consolidation of hospitals into massive chains threatens healthy competition, reduces patient choice and could drive up medical expenses. [More]

Newly developed oxidation process uses ozone to degrade contaminants in water

At the Center for Research and Assistance in Technology and Design of the State of Jalisco (CIATEJ) at the east of Mexico, an oxidation process was developed that uses ozone to degrade contaminants in water that alter the synthesis, transport, action or elimination of natural hormones, responsible for maintain self-regulation of metabolic and reproductive processes in living beings. [More]
Mylan sued in connection with ANDA filing for generic version of Zytiga

Mylan sued in connection with ANDA filing for generic version of Zytiga

Mylan N.V. today confirmed that the company has been sued by BTG International Ltd., Janssen Biotech, Inc., Janssen Oncology, Inc., and Janssen Research & Development, LLC in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration for Abiraterone Acetate Tablets, 250 mg. [More]
Dr. Samadi's Prostate Cancer Center now offers Oncotype DX genetic test

Dr. Samadi's Prostate Cancer Center now offers Oncotype DX genetic test

Revolutionary genetic test, Oncotype DX from Genomic Health, is now offered at Dr. Samadi's Prostate Cancer Center in New York City. [More]
Regulation of tumor microenvironment may offer alternate method for cancer treatment

Regulation of tumor microenvironment may offer alternate method for cancer treatment

Scientists know that activation of growth factor receptors like epidermal growth factor receptors (EGFR) promote tumor progression in many types of cancer. [More]
Genomic Health announces Medicare coverage for Oncotype DX prostate cancer test

Genomic Health announces Medicare coverage for Oncotype DX prostate cancer test

Genomic Health, Inc. today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued its final local coverage determination (LCD) approving coverage of the Oncotype DX prostate cancer test for qualified Medicare patients throughout the United States. [More]
FGF protein may play key role in breast and prostate cancer, shows research

FGF protein may play key role in breast and prostate cancer, shows research

Simply put, cancer is caused by mutations to genes within a cell that lead to abnormal cell growth. Finding out what causes that genetic mutation has been the holy grail of medical science for decades. [More]
New MRI contrast agent detects tiny breast cancer tumors, micrometastases

New MRI contrast agent detects tiny breast cancer tumors, micrometastases

Researchers at Case Western Reserve University have developed a magnetic resonance imaging (MRI) contrast agent that detects much smaller aggressive breast cancer tumors and micrometastases than current agents can identify. [More]
UNMCC receives NCI Comprehensive Cancer Center designation for cancer treatment, research programs

UNMCC receives NCI Comprehensive Cancer Center designation for cancer treatment, research programs

The University of New Mexico Cancer Center has been awarded the highest designation and rating in the United States for cancer treatment and research programs. It has received the National Cancer Institute's "NCI Comprehensive Cancer Center" designation, identifying it as one of the leading cancer centers in the nation and the only such cancer center in New Mexico. [More]
New approach may offer improved way to detect early breast cancer

New approach may offer improved way to detect early breast cancer

Researchers have shown that magnetic resonance imaging (MRI) can detect the earliest signs of breast cancer recurrence and fast-growing tumors. Their approach detects micromestastases, breakaway tumor cells with the potential to develop into dangerous secondary breast cancer tumors elsewhere in the body. [More]
Researcher study potential biomarker to determine patients at risk for aggressive breast cancer

Researcher study potential biomarker to determine patients at risk for aggressive breast cancer

Biomarkers are an important part in detecting certain cancers such as the BRCA gene in breast cancer and the PSA antigen in prostate cancer. They are easy to identify in a blood test and can help in diagnosing and giving a prognosis. [More]
Cost of radiation therapy varies widely among Medicare patients with cancer

Cost of radiation therapy varies widely among Medicare patients with cancer

Cost of radiation therapy among Medicare patients varied most widely because of factors unrelated to a patient or that person's cancer, report University of California, San Diego School of Medicine researchers in the Journal of Oncology Practice. [More]
Advertisement